Vera Therapeutics (Nasdaq:VERA) - Prezzo delle azioni, notizie e analisi

VERA Panoramica delle azioni

VERA analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Negoziato a 88.7% al di sotto della nostra stima del suo valore equo

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Gli azionisti sono stati diluiti nell'ultimo anno

Vera Therapeutics, Inc. Concorrenti

VitaSpring Biomedical

OTCPK:VSBC

US$3.1b

Dyne Therapeutics

NasdaqGS:DYN

US$3.1b

Agios Pharmaceuticals

NasdaqGS:AGIO

US$3.1b

Xenon Pharmaceuticals

NasdaqGM:XENE

US$3.0b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Vera Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$47.03
Massimo di 52 settimane	US$51.61
Minimo di 52 settimane	US$12.28
Beta	1.02
1Variazione di 1 mese	15.52%
Variazione a 3 mesi	19.67%
Variazione di 1 anno	257.37%
3Variazione a 3 anni	77.47%
Variazione a 5 anni	n/a
Variazione dall'IPO	308.96%

Notizie e aggiornamenti recenti

Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?

Oct 07

Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients

Oct 04

Recent updates

Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Feb 16

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Jan 19

Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot

Jan 07

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Oct 25

Vera Therapeutics soars 16% on three new favorable view from analysts

Jun 08

Rendimenti per gli azionisti

	VERA	US Biotechs	US Mercato
7D	-4.0%	-3.7%	0.3%
1Y	257.4%	15.2%	31.1%

Ritorno vs Industria: VERA ha superato il US Biotechs che ha restituito 15.2 % nell'ultimo anno.

Rendimento vs Mercato: VERA ha superato il mercato US che ha restituito 31.1 % nell'ultimo anno.

Volatilità dei prezzi

Is VERA's price volatile compared to industry and market?
VERA volatility
VERA Average Weekly Movement	8.5%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: VERA non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 8% ) di VERA è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2016	82	Marshall Fordyce	veratx.com

Vera Therapeutics, Inc. è una società di biotecnologie in fase clinica che si occupa dello sviluppo e della commercializzazione di trattamenti per pazienti affetti da gravi malattie immunologiche. Il suo principale prodotto candidato è atacicept, una proteina di fusione autosomministrata sotto forma di iniezione sottocutanea, in fase di sperimentazione clinica di Fase III per i pazienti affetti da nefropatia da immunoglobuline A e per il trattamento della nefrite da lupus, in fase di sperimentazione clinica di Fase II. Sta inoltre sviluppando MAU868, un anticorpo monoclonale umano per il trattamento delle infezioni da viremia BK.

Vera Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Vera Therapeutics con la sua capitalizzazione di mercato?
VERA statistiche fondamentali
Capitalizzazione di mercato	US$2.90b
Guadagni(TTM)	-US$134.38m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-22.2x

Rapporto P/E

VERA è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
VERA Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$134.38m
Guadagni	-US$134.38m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-2.12
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	17.5%

Come si è comportato VERA nel lungo periodo?

Vedi performance storica e confronto

VERA Panoramica delle azioni

Premi

Analisi del rischio

Vera Therapeutics, Inc. Concorrenti

OTCPK:VSBC

US$3.1b

NasdaqGS:DYN

US$3.1b

NasdaqGS:AGIO

US$3.1b

NasdaqGM:XENE

US$3.0b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Vera Therapeutics, Inc. Appoints Jason S. Carter as Chief Legal Officer

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.000036 million.

Vera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Vera Therapeutics, Inc. Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN at the American Society of Nephrology Kidney Week 2024

Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?

Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients

Recent updates

Vera Therapeutics, Inc. Appoints Jason S. Carter as Chief Legal Officer

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.000036 million.

Vera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Vera Therapeutics, Inc. Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN at the American Society of Nephrology Kidney Week 2024

Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?

Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients

Vera Therapeutics, Inc. Announces Expanded Atacicept Development Program in Multiple Autoimmune Kidney Diseases

Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA Nephropathy

Is Vera Therapeutics (NASDAQ:VERA) Using Debt In A Risky Way?

Vera Therapeutics, Inc.(NasdaqGM:VERA) dropped from Russell 3000E Value Index

Vera Therapeutics, Inc. Announces Appointment of David L. Johnson as Chief Operating Officer

Vera Therapeutics, Inc. Appoints Christy Oliger to the Board

Vera Therapeutics, Inc. Presents 72-Week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

Insider exercised options and sold US$1.0m worth of stock

Insider recently sold US$229k worth of stock

Price target increased by 17% to US$55.80

Chief Financial Officer recently sold US$735k worth of stock

Chief Financial Officer notifies of intention to sell stock

Vera Therapeutics, Inc., Annual General Meeting, May 15, 2024

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.000027 million.

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.000027 million.

Vera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Price target increased by 36% to US$32.11

New minor risk - Share price stability

Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect

Vera Therapeutics, Inc. Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b Origin Clinical Trial Ole in IgA Nephropathy

Vera Therapeutics, Inc. Announces Executive Changes

New minor risk - Share price stability

Price target increased by 12% to US$22.14

New major risk - Revenue and earnings growth

Price target increased by 16% to US$18.50

Price target increased by 10% to US$16.00

Price target decreased by 10% to US$14.50

New minor risk - Share price stability

Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

Price target decreased by 18% to US$15.67

Chief Financial Officer recently bought US$100k worth of stock

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Vera Therapeutics, Inc. Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Vera Therapeutics, Inc. Hosting A Key Opinion Leader Webinar on Atacicept for the Treatment Iga Nephropathy (Igan)

Price target decreased to US$19.17

Vera Therapeutics, Inc. Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Chief Development Officer exercised options and sold US$148k worth of stock

Founder exercised options to buy US$1.1m worth of stock.

High number of new directors

Chief Development Officer exercised options and sold US$95k worth of stock

Founder exercised options and sold US$576k worth of stock

Chief Development Officer exercised options and sold US$186k worth of stock

Founder exercised options and sold US$622k worth of stock

Vera Therapeutics: Under The Radar IgAN Player Has Much To Prove

Founder exercised options and sold US$354k worth of stock

Vera Therapeutics GAAP EPS of -$0.55 beats by $0.17

Vera Therapeutics Completes Patient Enrollment in Phase 2B Origin Clinical Trial of Atacicept for the Treatment of Iga Nephropathy

Chief Financial Officer recently bought US$68k worth of stock

Vera Therapeutics, Inc. Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients

High number of new directors

Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus

High number of new directors